Daily doses of obicetrapib over 52 weeks led to significant reductions in plasma p-tau217 and other Alzheimer’s disease ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Last winter, I donated my kidney to a stranger. As a nephrologist, I see people every day who need a gently used kidney, and ...

AbbVie released positive topline data from its phase 3 UP-AA trial demonstrating safety and efficacy for upadacitinib for ...

Exercise-based cardiac rehabilitation may improve symptom burden, exercise capacity and health-related quality of life for ...

Patients with type 2 diabetes are more likely to experience adverse financial outcomes such as having a low credit score, ...

Most children hospitalized for COVID-19 had at least one underlying condition and less than 4% were up to date on COVID-19 ...

Patients receiving prolonged mechanical ventilation discharged from the ICU had better outcomes related to 6-month mortality ...

Esophageal dilation may confound the association between histologic outcomes and symptom response or endoscopic efficacy ...

Education about immune-related adverse events associated with checkpoint inhibitor therapy for cancer is essential for every ...

Re-Vana Therapeutics is collaborating with Boehringer Ingelheim to develop extended-release therapies for ophthalmic diseases ...

A controversial hematologist-oncologist who joined FDA this spring and quickly became its top regulator has left the ...